Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13113282 | 0.93 | NPC1 (0.46) | NPC1RAB9APKMMTNR1AMTNR1B | |
| SCHEMBL13113352 | 0.91 | NPC1 (0.45) | NPC1RAB9APKMMTNR1AMTNR1B | |
| SCHEMBL3481095 | 0.91 | NPC1 (0.45) | NPC1RAB9APKMMTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL3481287 | 0.90 | NPC1 (0.44) | NPC1RAB9APKMMTNR1AMTNR1B | |
| SCHEMBL13113367 | 0.88 | NPC1 (0.46) | NPC1RAB9APKMMTNR1AMTNR1B | |
| SCHEMBL3481901 | 0.86 | NPC1 (0.50) | NPC1RAB9APKMHTR2CHTR2A | |
| SCHEMBL3481186 | 0.86 | NPC1 (0.44) | NPC1RAB9APKMMTNR1AMTNR1B | |
| SCHEMBL13113446 | 0.86 | MTNR1A (0.66) | NPC1RAB9APKMMTNR1AMTNR1B | |
| SCHEMBL13113315 | 0.83 | NPC1 (0.46) | NPC1RAB9APKMMTNR1AMTNR1B | |
| SCHEMBL13113311 | 0.81 | NPC1 (0.47) | NPC1RAB9APKMMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267712-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | The United States of America, as represented by the Secretary, Department of Health and | 2010-10-21 | — | — | US | disclosed |
| US-20100267712-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | The United States of America, as represented by the Secretary, Department of Health and | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267712-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | SMN1; SMN2, SYNCRIP, RNMT | NPC1 1441/4885RAB9A 985/4885PKM 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.